JP2022546813A5 - - Google Patents
Info
- Publication number
- JP2022546813A5 JP2022546813A5 JP2022513855A JP2022513855A JP2022546813A5 JP 2022546813 A5 JP2022546813 A5 JP 2022546813A5 JP 2022513855 A JP2022513855 A JP 2022513855A JP 2022513855 A JP2022513855 A JP 2022513855A JP 2022546813 A5 JP2022546813 A5 JP 2022546813A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025142204A JP2025172875A (ja) | 2019-09-04 | 2025-08-28 | パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962895727P | 2019-09-04 | 2019-09-04 | |
| US62/895,727 | 2019-09-04 | ||
| PCT/US2020/049183 WO2021046207A1 (en) | 2019-09-04 | 2020-09-03 | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025142204A Division JP2025172875A (ja) | 2019-09-04 | 2025-08-28 | パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022546813A JP2022546813A (ja) | 2022-11-09 |
| JPWO2021046207A5 JPWO2021046207A5 (https=) | 2023-09-07 |
| JP2022546813A5 true JP2022546813A5 (https=) | 2023-09-07 |
| JP7818504B2 JP7818504B2 (ja) | 2026-02-20 |
Family
ID=72521748
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513855A Active JP7818504B2 (ja) | 2019-09-04 | 2020-09-03 | パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用 |
| JP2025142204A Pending JP2025172875A (ja) | 2019-09-04 | 2025-08-28 | パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025142204A Pending JP2025172875A (ja) | 2019-09-04 | 2025-08-28 | パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220306697A1 (https=) |
| EP (1) | EP4025587A1 (https=) |
| JP (2) | JP7818504B2 (https=) |
| CN (1) | CN114502572A (https=) |
| WO (1) | WO2021046207A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023133435A2 (en) * | 2022-01-07 | 2023-07-13 | University Of Washington | Novel immunogens for influenza virus vaccines |
| AU2023273041A1 (en) * | 2022-05-17 | 2024-12-05 | Icosavax, Inc. | Multivalent vaccine for paramyxoviruses and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2707385T3 (da) | 2011-05-13 | 2017-11-20 | Glaxosmithkline Biologicals Sa | RSV-F-præfusionsantigener |
| EA201590683A1 (ru) | 2012-11-20 | 2015-11-30 | Глаксосмитклайн Байолоджикалс С.А. | Тримеры rsv f, предшествующие слиянию |
| US20140141037A1 (en) | 2012-11-20 | 2014-05-22 | Novartis Ag | Rsv f prefusion trimers |
| US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| FI2970398T3 (fi) | 2013-03-13 | 2024-08-06 | Us Health | Rsv f -prefuusioproteiineja ja niiden käyttö |
| US9060975B2 (en) | 2013-03-14 | 2015-06-23 | Mucosis Bv | Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions |
| JP6469081B2 (ja) | 2013-04-25 | 2019-02-13 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 安定化された可溶性融合前ｒｓｖｆポリペプチド |
| MY171210A (en) | 2013-06-17 | 2019-10-02 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f polypeptides |
| US20150166610A1 (en) | 2013-10-14 | 2015-06-18 | Glaxosmithkline Biologicals, S.A. | Recombinant rsv antigens |
| CA2996762A1 (en) | 2015-08-31 | 2017-03-09 | Technovax, Inc. | Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine |
| EP3393512B1 (en) | 2015-12-23 | 2025-11-19 | Pfizer Inc. | Rsv f protein mutants |
| US11174292B2 (en) | 2016-03-29 | 2021-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Substitutions-modified prefusion RSV F proteins and their use |
| IL264119B2 (en) | 2016-05-30 | 2023-04-01 | Janssen Vaccines Prevention B V | f proteins of rsv are stabilized before fusion |
| WO2017207477A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
| US10818377B2 (en) * | 2016-11-16 | 2020-10-27 | University Of Washington | Computational design of self-assembling cyclic protein homo-oligomers |
| KR102774312B1 (ko) * | 2017-04-04 | 2025-03-05 | 유니버시티 오브 워싱톤 | 파라믹소바이러스 및/또는 뉴모바이러스 f 단백질을 표시하는 자가-조립 단백질 나노구조체 및 이의 용도 |
-
2020
- 2020-09-03 CN CN202080068157.1A patent/CN114502572A/zh active Pending
- 2020-09-03 WO PCT/US2020/049183 patent/WO2021046207A1/en not_active Ceased
- 2020-09-03 EP EP20772512.8A patent/EP4025587A1/en active Pending
- 2020-09-03 JP JP2022513855A patent/JP7818504B2/ja active Active
- 2020-09-03 US US17/639,442 patent/US20220306697A1/en active Pending
-
2025
- 2025-08-28 JP JP2025142204A patent/JP2025172875A/ja active Pending